Terms: = Colorectal cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Clinical Outcome
10 results:
1. clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment.
Suwanthanma W; Kitudomrat S; Euanorasetr C
Medicine (Baltimore); 2021 Sep; 100(38):e27366. PubMed ID: 34559161
[TBL] [Abstract] [Full Text] [Related]
2. The TIM-3 Rs10053538 Polymorphism Is Associated with clinical Prognosis of colorectal cancer.
Liu Y; Duan Y; Yang N; Li B; Kong D
Immunol Invest; 2022 Jul; 51(5):1302-1312. PubMed ID: 34080945
[TBL] [Abstract] [Full Text] [Related]
3. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma.
Hackl C; Neumann P; Gerken M; Loss M; Klinkhammer-Schalke M; Schlitt HJ
BMC Cancer; 2014 Nov; 14():810. PubMed ID: 25369977
[TBL] [Abstract] [Full Text] [Related]
4. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
[TBL] [Abstract] [Full Text] [Related]
5. Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab.
Ricotta R; Vanzulli A; Moroni M; Colnago B; Oriani M; Nichelatti M; Sarnataro C; Venturini F; Di Bella S; Maiolani M; Giganti MO; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2013 Mar; 12(1):45-53. PubMed ID: 23041354
[TBL] [Abstract] [Full Text] [Related]
6. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer.
Bauer K; Nitsche U; Slotta-Huspenina J; Drecoll E; von Weyhern CH; Rosenberg R; Höfler H; Langer R
Cell Oncol (Dordr); 2012 Jun; 35(3):197-205. PubMed ID: 22535481
[TBL] [Abstract] [Full Text] [Related]
7. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
[TBL] [Abstract] [Full Text] [Related]
8. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
Backus HH; van Riel JM; van Groeningen CJ; Vos W; Dukers DF; Bloemena E; Wouters D; Pinedo HM; Peters GJ
Ann Oncol; 2001 Jun; 12(6):779-85. PubMed ID: 11484952
[TBL] [Abstract] [Full Text] [Related]
9. Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance.
Pagès F; Berger A; Henglein B; Piqueras B; Danel C; Zinzindohoue F; Thiounn N; Cugnenc PH; Fridman WH
Int J Cancer; 1999 Jun; 84(3):326-30. PubMed ID: 10371355
[TBL] [Abstract] [Full Text] [Related]
10. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival.
Gansler TS; Hardman W; Hunt DA; Schaffel S; Hennigar RA
Hum Pathol; 1997 Jun; 28(6):686-92. PubMed ID: 9191002
[TBL] [Abstract] [Full Text] [Related]
